Your therapy is unique and important to patients. At NECSTGEN we enable the next generation of therapies by offering development support and GMP production of cell and gene therapies.
The rapid developments in cell and gene therapy research and the industry as a whole provide remedies to increasingly more patients while offering the potential to decrease the burden on society. NECSTGEN will support clinicians, academic groups and small industrial therapy developers globally to bring cell and gene therapies to patients.
Today, the Dutch cabinet announced the investment of €56 million into the establishment of a “pilot factory” for regenerative therapies. NecstGen and three other facilities will form a chain covering the development and…
Markwin Velders brings 20 years of experience in cell and gene therapy. He is Chairman of HollandBIO and co-founder of various biotech companies. As VP Operation at Kite Pharma, he led the establishment of a large scale CAR-T manufacturing site…
Sander van Deventer is professor of Translational gastroenterology at the LUMC and partner at Forbion. Among others, he co-founded gene therapy developer uniQure and played a crucial role in the commercialization of the first gene therapy Glybera.
League of European Research Universities (LERU):
Improve patient access to Advanced Therapy Medicinal Products